Acetylcysteine synergizes PD-1 blockers against colorectal cancer progression by promoting TCF1+PD1+CD8+ T cell differentiation
Our study provides a novel idea for immunotherapy for clinically progressive CRC and suggests that Glut4 may be a new immunometabolic molecular target for regulating CD8<sup>+</sup> T cell differentiation.
Authors
- Xingfeng Sun (ORCID: https://orcid.org/0000-0003-3078-5681)
- Ying Yue (ORCID: https://orcid.org/0000-0001-5378-7570)
- Changhong Miao (ORCID: https://orcid.org/0000-0002-2809-6599)
- Ke Nan (ORCID: https://orcid.org/0000-0002-5691-0295)
- Jie Zhang (ORCID: https://orcid.org/0000-0001-7455-0492)
- Wenchang Zhou (ORCID: https://orcid.org/0000-0002-5819-4296)
- Wankun Chen (ORCID: https://orcid.org/0000-0001-7394-9266)
- Ziwen Zhong (ORCID: https://orcid.org/0000-0002-4578-174X)
- Qichao Wu
- Mengdi Qu
Institutions
- Fudan University (CN)
- Zhongshan Hospital (CN)
- Obstetrics and Gynecology Hospital of Fudan University (CN)
Publication Details
- Journal
- Cell Communication and Signaling
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1186/s12964-024-01848-8
- Citations
- 7
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.98
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China